Shanghai Pharma in Second Round Bidding for $1.5 Billion Cardinal China Deal

Shanghai Pharma and FountainVest Partners, a China private equity fund, have submitted second-round bids for Cardinal China's drug distribution operations. According to a Bloomberg article, the two entities are part of a smaller group of still-interested bidders that also includes Warburg Pincus of the US and PAG Asia Capital, a China/Asia investor. Cardinal China's operations are expected to draw bids in the $1-$1.5 billion range, though Cardinal may keep its China operations if it doesn't receive a suitable bid. More details.... Stock Symbols: (SHA: 601607) (NYSE: CAH) Share this with colleagues: // //